Trial Profile
A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Children and Adults Ages 3 to 64 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Novartis Vaccines
- 20 May 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 20 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Dec 2009 Interim results published in the New England Journal of Medicine : 30 Dec 2009